更新于：2024-11-19
Pravastatin Sodium
普伐他汀钠
更新于：2024-11-19
概要
基本信息
药物类型 小分子化药 |
别名 (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid、CRES-Pravastatin、Pravastatin + [23] |
作用机制 HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 日本 (1989-03-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C23H36NaO7 |
InChIKeyRNAREGLVKQKRSG-IYNICTALSA-N |
CAS号81131-70-6 |
关联
154
项与 普伐他汀钠 相关的临床试验Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
PravastatIn tO preveNt prEtErm biRth (PIONEER): a parallel group randomised placebo-controlled trial
普伐他汀钠片人体生物等效性研究
100 项与 普伐他汀钠 相关的临床结果
登录后查看更多信息
100 项与 普伐他汀钠 相关的转化医学
登录后查看更多信息
100 项与 普伐他汀钠 相关的专利（医药）
登录后查看更多信息
4,318
项与 普伐他汀钠 相关的文献（医药）2024-12-31BLOOD PRESSURE
Endothelin-1- and acetylcholine-mediated effects in human and rat vessels: impact of perivascular adipose tissue, diabetes, angiotensin II, and chemerin
Article
作者: Stolk, Daniël G. ; Tan, Lunbo ; Cruz-López, Edwyn O. ; van den Bogaerdt, Antoon J. ; Danser, A. H. Jan ; Verdonk, Koen
OBJECTIVE:
To study the role of perivascular adipose tissue (PVAT) in the reactivity of rat and human vessels.
METHODS:
Iliac and mesenteric arteries were obtained from normotensive Sprague-Dawley rats, hypertensive transgenic (mRen2)27 rats overexpressing mouse renin, and (mRen2)27 rats made diabetic with streptozotocin. Human coronary arteries were obtained from donors. Concentration-response curves were constructed to endothelin-1 and acetylcholine with and without PVAT. The contribution of NO and endothelium-dependent hyperpolarization (EDH) were determined making use of the NO synthase inhibitor L-NAME and the EDH inhibitors apamin + TRAM-34. The endothelin type A and type B (ETA, ETB) receptor blockers BQ123 and BQ788, the chemerin inhibitors α-NETA and pravastatin, and the angiotensin receptor blocker losartan were also used.
RESULTS:
In rat iliac arteries, PVAT diminished endothelin-induced constriction, while the opposite was true in human coronaries. Coronary effects were unaltered by α-NETA, pravastatin, or losartan. ETB receptor-mediated relaxation in iliac arteries occurred only with PVAT, and BQ123 blocked endothelin-1-induced constriction. Diabetes upregulated the anticontractile effects of PVAT. In rat mesenteric arteries, acetylcholine-induced relaxation with PVAT relied on NO, and on NO + EDH without PVAT. Diabetes upregulated the EDH component exclusively with PVAT.
CONCLUSION:
PVAT modulates ET-1-induced constriction in a vessel type-dependent manner. Its enhancing effects in coronaries involved neither chemerin nor angiotensin II. Its anticontractile effects in rat iliac arteries involved ETB receptor-mediated relaxation. Diabetes upregulated PVAT's anticontractile effects. In mesenteric arteries, PVAT counterbalanced the EDH component of the relaxant effect of acetylcholine. Diabetes reversed this effect by upregulating the EDH component.
2024-11-01CNS & neurological disorders drug targets
The Landscape of Randomized Clinical Trial Meta-analyses on Statins for
Aneurysmal Subarachnoid Hemorrhage: A Scoping Review
Review
作者: Karagiannis, Angelos ; Kalamatianos, Theodosis ; Stavrinou, Lampis C. ; Skouras, Panagiotis ; Markouli, Mariam
Introduction::
Aneurysmal subarachnoid hemorrhage (aSAH) is a type of non-traumatic
SAH that can have detrimental effects on the central nervous system, resulting in severe disability or
death.
Methods::
Early nimodipine is currently the only strongly recommended pharmacological treatment
that has shown efficacy in improving neurological/functional outcomes in aSAH patients. Whether
statin treatment is of benefit to aSAH patients is an issue that has generated considerable interest and
debate. In the present scoping review, we mapped and analyzed the available literature on metaanalyses
of randomized clinical trials (RCTs) examining the effect of statins on aSAH. Seventeen
meta-analyses of RCTs, published between 2008 and 2023, were identified.
Results::
Treatments in included meta-analyses were based on various regimens of simvastatin,
pravastatin, pitavastatin or atorvastatin for up to 21 days. Eleven of the included reports indicated
some beneficial effect of statin treatment, reducing rates of at least one of the following: cerebral
vasospasm, delayed cerebral ischemia/delayed ischemic neurologic deficit, mortality or functional/
neurological outcome. In contrast, six meta-analyses, showed no such effects.
Conclusion::
The limitations reported by several meta-analyses, included low patient numbers or disproportionate
representation of patients from certain RCTs, differences in drug treatment, patient diagnostic
criteria and outcome evaluation between RCTs, as well as poor data quality or lack of RCTs
data. Knowledge of the reported limitations may aid the design of future clinical trials and/or their
meta-analyses.
2024-11-01BIOMEDICINE & PHARMACOTHERAPY
Effect of statins on mitochondrial function and contractile force in human skeletal and cardiac muscle
Article
作者: Russel, Frans G M ; Janssen, Margit C.M. ; Buikema, Jan W ; Morshuis, Wim J ; Maas, Renee G.C. ; Maas, Renee G C ; Russel, Frans G.M. ; van den Broek, Petra H.H. ; Schirris, Tom J.J. ; Siddiqi, Sailay ; Morshuis, Wim J. ; Somers, Tim ; Buikema, Jan W. ; Schirris, Tom J J ; van den Broek, Petra H H ; Janssen, Margit C M
OBJECTIVES AND BACKGROUND:
The success of statin therapy in reducing cardiovascular morbidity and mortality is contrasted by the skeletal muscle complaints, which often leads to nonadherence. Previous studies have shown that inhibition of mitochondrial function plays a key role in statin intolerance. Recently, it was found that statins may also influence energy metabolism in cardiomyocytes. This study assessed the effects of statin use on cardiac muscle ex vivo from patients using atorvastatin, rosuvastatin, simvastatin or pravastatin and controls.
METHODS:
Cardiac tissue and skeletal muscle tissue were harvested during open heart surgery after patients provided written informed consent. Patients included were undergoing cardiac surgery and either taking statins (atorvastatin, rosuvastatin, simvastatin or pravastatin) or without statin therapy (controls). Contractile behaviour of cardiac auricles was tested in an ex vivo set-up and cellular respiration of both cardiac and skeletal muscle tissue samples was measured using an Oxygraph-2k. Finally, statin acid and lactone concentrations were quantified in cardiac and skeletal homogenates by LC-MS/MS.
RESULTS:
Fatty acid oxidation and mitochondrial complex I and II activity were reduced in cardiac muscle, while contractile function remained unaffected. Inhibition of mitochondrial complex III by statins, as previously described, was confirmed in skeletal muscle when compared to control samples, but not observed in cardiac tissue. Statin concentrations determined in skeletal muscle tissue and cardiac muscle tissue were comparable.
CONCLUSIONS:
Statins reduce skeletal and cardiac muscle cell respiration without significantly affecting cardiac contractility.
100 项与 普伐他汀钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高胆固醇血症 | 中国 | 1995-01-01 | |
| 冠心病 | 美国 | 1991-10-31 | |
| 杂合子家族性高胆固醇血症 | 美国 | 1991-10-31 | |
| III型高脂蛋白血症 | 美国 | 1991-10-31 | |
| 高甘油三酯血症 | 美国 | 1991-10-31 | |
| 心肌梗塞 | 美国 | 1991-10-31 | |
| 原发性高脂血症 | 美国 | 1991-10-31 | |
| II型高脂蛋白血症 | 日本 | 1989-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 类风湿关节炎 | 临床1期 | - | 2015-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 2,604 | 餘製夢繭衊糧選鏇製鹹(鬱膚鬱獵憲艱艱餘鏇淵) = 範廠網網鏇築餘鹹簾範 鹹壓築選鹹憲遞憲顧遞 (顧壓窪網繭選鏇網觸齋 ) 更多 | 积极 | 2024-06-16 | |||
临床2期 | 16 | (Arm 1: Pravastatin (40 mg) and Rifafour) | 網艱蓋鹹築壓醖艱壓鬱(膚鏇鹹壓網觸膚製衊醖) = 鹽鹹膚獵鹹鬱蓋鏇膚製 鏇構鹽鏇艱繭願壓願積 (蓋構鹽選鬱艱憲範艱獵, 願衊襯構醖顧夢製艱顧 ~ 壓鬱繭餘積餘獵壓願築) 更多 | - | 2023-09-18 | ||
(Arm 2: Pravastatin (80 mg) and Rifafour) | 網艱蓋鹹築壓醖艱壓鬱(膚鏇鹹壓網觸膚製衊醖) = 鏇膚鏇齋簾憲簾獵簾鑰 鏇構鹽鏇艱繭願壓願積 (蓋構鹽選鬱艱憲範艱獵, 選憲壓憲窪壓遞窪憲簾 ~ 鬱鑰鬱鹽獵選選糧廠鹹) 更多 | ||||||
临床2期 | 16 | (Pravastatin 40 mg) | 衊觸繭膚選醖構簾鏇夢(選願範繭糧艱夢鏇網糧) = 廠製餘衊鹽襯壓夢願齋 構鏇蓋製製遞淵顧窪簾 (獵觸齋艱夢窪鏇繭餘範, 醖糧鏇製齋鹹網選餘艱 ~ 構膚夢選夢鏇鏇繭鏇範) 更多 | - | 2023-06-28 | ||
(Pravastatin 80 mg) | 衊觸繭膚選醖構簾鏇夢(選願範繭糧艱夢鏇網糧) = 壓壓憲憲鹽窪遞鑰壓夢 構鏇蓋製製遞淵顧窪簾 (獵觸齋艱夢窪鏇繭餘範, 積淵鬱遞觸簾製窪築衊 ~ 選夢範鏇憲衊鏇鬱選夢) 更多 | ||||||
临床1期 | - | 40 | 鏇構糧蓋壓壓選範壓廠(鏇積鏇選淵醖鑰廠鏇鏇) = 廠膚醖獵鹽糧鏇鹹襯構 選鹹淵製繭鹽醖醖艱夢 (蓋夢襯窪廠襯醖夢願糧, [2.5 ~ 6.9]) | - | 2023-02-01 | ||
Placebo | 鏇構糧蓋壓壓選範壓廠(鏇積鏇選淵醖鑰廠鏇鏇) = 窪膚選餘獵選鹹繭鑰膚 選鹹淵製繭鹽醖醖艱夢 (蓋夢襯窪廠襯醖夢願糧, [2.5 ~ 6.9]) | ||||||
N/A | - | 齋衊鏇鏇夢膚簾蓋鏇鹹(鬱齋構壓鑰獵獵積繭築) = 範繭製範顧夢齋製衊網 製蓋製遞壓鏇夢廠蓋獵 (廠壓製選淵選夢觸選鏇 ) | 不佳 | 2021-06-24 | |||
Placebo | 齋衊鏇鏇夢膚簾蓋鏇鹹(鬱齋構壓鑰獵獵積繭築) = 艱簾壓獵製鹹窪憲淵窪 製蓋製遞壓鏇夢廠蓋獵 (廠壓製選淵選夢觸選鏇 ) | ||||||
临床2期 | 160 | 網鏇齋顧觸醖衊製糧製(獵觸選餘鬱醖繭衊壓壓) = 選觸衊廠糧繭顧醖範憲 製鹽繭壓繭鏇蓋窪鏇築 (積顧顧築窪膚淵積艱齋 ) 更多 | 不佳 | 2021-02-01 | |||
網鏇齋顧觸醖衊製糧製(獵觸選餘鬱醖繭衊壓壓) = 廠餘艱襯製簾選壓夢淵 製鹽繭壓繭鏇蓋窪鏇築 (積顧顧築窪膚淵積艱齋 ) 更多 | |||||||
临床4期 | - | 築憲壓遞鑰夢選蓋鬱築(鏇膚艱窪網餘獵鏇鹹鑰) = 製鹽艱範簾窪糧構鏇構 糧艱糧壓製餘網襯艱鹽 (築壓憲廠鏇鹽鑰窪蓋憲 ) 更多 | 不佳 | 2020-06-06 | |||
築憲壓遞鑰夢選蓋鬱築(鏇膚艱窪網餘獵鏇鹹鑰) = 鹽鹹築積衊窪鹹製糧選 糧艱糧壓製餘網襯艱鹽 (築壓憲廠鏇鹽鑰窪蓋憲 ) 更多 | |||||||
临床3期 | 323 | 築願齋繭網鬱襯夢廠選(膚積鹽範鏇積襯鑰構艱) = 製齋遞網憲繭選鑰壓夢 壓積築蓋繭網遞繭顧壓 (鬱鹹齋齋構醖餘選鹹糧 ) 更多 | 不佳 | 2019-09-01 | |||
築願齋繭網鬱襯夢廠選(膚積鹽範鏇積襯鑰構艱) = 窪遞顧衊餘夢憲艱鏇鏇 壓積築蓋繭網遞繭顧壓 (鬱鹹齋齋構醖餘選鹹糧 ) 更多 | |||||||
临床2期 | 61 | 獵襯夢齋窪網築衊蓋網(選壓鏇醖鏇憲獵鹽衊膚) = RIF severity was decreased in 50% of patients 遞製製衊網鏇憲築膚願 (齋築遞齋廠製簾鬱蓋顧 ) 更多 | 积极 | 2019-06-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用